Elite Journal of Haematology. Volume 2 issue 5(2024), Pp. 90-107
https://epjournals.com/journals/EJH

Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Hemophilia patients with concurrent HIV infection face a unique set of challenges, including hematological complications that extend beyond traditional coagulation abnormalities. This review examines the current understanding of erythrocyte morphology changes in individuals with hemophilia and HIV co-infection, shedding light on the underlying mechanisms, clinical implications, and management considerations. Erythrocyte alterations in this population are increasingly recognized, contributing to the complexity of their clinical presentation and treatment. Chronic inflammation, immune dysregulation, and direct viral effects are among the key drivers of erythrocyte alterations observed in individuals with both hemophilia and HIV. Moreover, the dysregulation of coagulation pathways inherent in hemophilia may further exacerbate erythrocyte abnormalities, highlighting the intricate interplay between these two conditions. By elucidating the mechanistic underpinnings of erythrocyte morphology changes, clinicians can develop targeted interventions to mitigate hematological complications and improve patient outcomes. The clinical implications of erythrocyte morphology changes in hemophilia patients with HIV extend beyond traditional hematological parameters and underscore the need for tailored management strategies. Comprehensive assessment of erythrocyte parameters alongside routine hematological markers can enhance disease monitoring and treatment optimization in this complex patient population.

Introduction

Hemophilia, a rare inherited bleeding disorder characterized by deficient or dysfunctional coagulation factors, presents a significant clinical burden to affected individuals worldwide. The

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

hallmark feature of hemophilia is the propensity for prolonged and spontaneous bleeding, which can lead to debilitating joint damage, organ hemorrhage, and life-threatening complications if left untreated. While advancements in treatment modalities, including factor replacement therapy and gene therapy, have revolutionized the management of hemophilia, certain challenges persist, particularly in populations with concurrent comorbidities such as HIV infection. HIV, the causative agent of acquired immunodeficiency syndrome (AIDS), has had a profound impact on global health since its emergence in the early 1980s. Although the advent of highly active antiretroviral therapy (HAART) has transformed HIV infection from a once fatal illness to a chronic manageable condition, individuals living with HIV still face numerous medical and psychosocial challenges. Of particular concern are the hematological complications associated with HIV infection, including cytopenias, coagulation abnormalities, and erythrocyte morphological changes, which can exacerbate existing health conditions and complicate clinical management.[1-20]

A subset of individuals with hemophilia has been disproportionately affected by the HIV epidemic due to the widespread use of contaminated blood products before the implementation of rigorous screening protocols. As a result, co-infection with HIV is not uncommon in this population, posing unique challenges for healthcare providers. While much attention has been given to the impact of HIV on the coagulation cascade and bleeding phenotype in hemophilia patients, relatively little is known about its effects on erythrocyte morphology, despite emerging evidence suggesting a potential link between HIV infection and erythrocyte abnormalities. Erythrocytes, or red blood cells, are the most abundant cellular component of blood and play a crucial role in oxygen transport and tissue perfusion. Alterations in erythrocyte morphology, such as changes in size, shape, and membrane integrity, can have significant physiological consequences, impacting blood viscosity, rheology, and microvascular circulation. Therefore, investigating erythrocyte morphology changes in hemophilia patients with HIV co-infection holds promise for unraveling novel disease mechanisms and identifying potential therapeutic targets to improve patient outcomes.[21-40]

This review aims to provide a comprehensive overview of the current understanding of erythrocyte morphology changes in individuals with hemophilia and HIV co-infection.

Erythrocyte Morphology in Hemophilia

Hemophilia, a hereditary bleeding disorder characterized by deficiencies or dysfunction in clotting factors, is primarily associated with abnormalities in the coagulation cascade. However, emerging evidence suggests that hemophilia may also impact erythrocyte morphology, although this aspect of the disorder has received comparatively less attention. Erythrocytes, or red blood cells, play a crucial role in oxygen transport and tissue perfusion, and any alterations in their morphology can have significant physiological consequences. In hemophilia patients, chronic bleeding episodes and subsequent anemia can contribute to changes in erythrocyte size, shape, and membrane integrity, further complicating the clinical presentation of the disease. One of the most well-

documented erythrocyte abnormalities in hemophilia is microcytosis, characterized by a reduction in erythrocyte size. Chronic blood loss secondary to recurrent bleeding episodes leads to iron deficiency anemia, resulting in the production of smaller erythrocytes with decreased hemoglobin content. Additionally, alterations in erythropoiesis and iron metabolism may contribute to the development of microcytosis in hemophilia patients, further exacerbating their hematological complications. Microcytic erythrocytes are less efficient at oxygen delivery, potentially exacerbating tissue hypoxia and organ dysfunction in individuals with hemophilia. In addition to microcytosis, hemophilia patients may also exhibit abnormalities in erythrocyte shape, known as poikilocytosis. Poikilocytes, or irregularly shaped erythrocytes, can take various forms, including spherocytes, elliptocytes, and schistocytes, depending on the underlying pathophysiological processes. Chronic intravascular hemolysis and mechanical trauma associated with bleeding episodes can lead to the formation of poikilocytes in hemophilia patients, further contributing to their anemic state and increasing the risk of thrombotic complications. Furthermore, alterations in erythrocyte membrane integrity, such as decreased deformability and increased fragility, may impair their ability to traverse the microcirculation, exacerbating tissue ischemia and organ damage.[41-70]

Mechanisms Underlying Erythrocyte Morphology Alterations

The alterations in erythrocyte morphology observed in hemophilia patients result from a complex interplay of underlying pathophysiological mechanisms, which can be attributed to both the primary hemophilia disorder and secondary factors associated with bleeding episodes and comorbidities, such as HIV infection. Several key mechanisms contribute to these erythrocyte morphology alterations, including chronic anemia, iron deficiency, hemolysis, and inflammation, each of which impacts erythropoiesis, erythrocyte structure, and membrane integrity. Chronic anemia, a common complication of hemophilia due to recurrent bleeding episodes, plays a central role in erythrocyte morphology alterations. Prolonged blood loss leads to decreased hemoglobin levels and impaired oxygen-carrying capacity, prompting compensatory mechanisms to maintain tissue oxygenation. Consequently, the bone marrow increases erythropoiesis, resulting in the production of immature erythrocytes with smaller size (microcytosis) and reduced hemoglobin content. These microcytic erythrocytes are less efficient at oxygen delivery and may exhibit abnormal shapes due to rapid maturation and release into circulation.[71-90]

Iron deficiency is another significant contributor to erythrocyte morphology alterations in hemophilia patients. Chronic blood loss depletes iron stores, impairing erythropoiesis and leading to the development of microcytic, hypochromic erythrocytes. Iron deficiency also disrupts erythrocyte membrane integrity and stability, increasing their susceptibility to mechanical damage and hemolysis. Moreover, iron deficiency-induced erythrocyte fragility exacerbates oxidative stress and inflammation, further compromising erythrocyte morphology and function. Hemolysis, both intravascular and extravascular, is a common consequence of hemophilia-related bleeding episodes and may contribute to erythrocyte morphology alterations. Intravascular hemolysis,

resulting from mechanical trauma and shear stress within blood vessels, leads to the formation of fragmented erythrocytes (schistocytes) with abnormal shapes. Extravascular hemolysis, occurring primarily in the spleen and liver, removes damaged or senescent erythrocytes from circulation, resulting in the release of bilirubin and the formation of spherocytes. Chronic hemolysis exacerbates anemia and contributes to erythrocyte membrane damage, perpetuating the cycle of erythrocyte morphology alterations. Inflammation, a hallmark feature of hemophilia and HIV infection, further exacerbates erythrocyte morphology alterations through multiple pathways. Proinflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), disrupt erythropoiesis and erythrocyte maturation in the bone marrow, leading to the production of dysmorphic erythrocytes. Inflammatory mediators also promote oxidative stress and endothelial dysfunction, contributing to erythrocyte membrane damage and increased susceptibility to hemolysis. Additionally, chronic inflammation alters erythrocyte rheology and adhesion properties, further impairing their function and exacerbating tissue hypoxia.[91-120]

Clinical Implications and Management Considerations

The erythrocyte morphology alterations observed in hemophilia patients have significant clinical implications for disease monitoring, treatment optimization, and overall patient care. One of the primary clinical implications of erythrocyte morphology alterations in hemophilia patients is the potential exacerbation of anemia and tissue hypoxia. Microcytic erythrocytes with reduced hemoglobin content have decreased oxygen-carrying capacity, leading to tissue ischemia and organ dysfunction. Therefore, monitoring erythrocyte parameters, including mean corpuscular volume (MCV) and hemoglobin levels, is essential for assessing disease severity and guiding therapeutic interventions to mitigate anemia-related complications. Furthermore, erythrocyte morphology alterations may increase the risk of thrombotic events in hemophilia patients. Abnormal erythrocyte shapes, such as schistocytes and spherocytes, promote endothelial activation and platelet aggregation, predisposing individuals to microvascular thrombosis and venous thromboembolism. Therefore, clinicians should be vigilant for signs of thrombosis in hemophilia patients with erythrocyte morphology abnormalities and consider thromboprophylaxis strategies, especially in high-risk individuals.[121-140]

In addition to monitoring and prevention, management considerations for hemophilia patients with erythrocyte morphology alterations should include targeted therapeutic interventions aimed at addressing underlying hematological abnormalities. Treatment strategies may involve iron supplementation to correct iron deficiency and alleviate microcytosis, erythropoietin therapy to stimulate erythropoiesis and increase hemoglobin levels, and anti-inflammatory agents to mitigate erythrocyte damage and oxidative stress. Moreover, optimizing hemophilia management, including prophylactic factor replacement therapy and adherence to treatment regimens, is crucial for preventing bleeding episodes and reducing the need for blood transfusions, which can exacerbate erythrocyte-related complications. Additionally, addressing comorbidities, such as HIV infection, through antiretroviral therapy and management of opportunistic infections, can

mitigate inflammatory responses and improve erythrocyte morphology in co-infected individuals. Finally, patient education and supportive care play a pivotal role in managing erythrocyte morphology alterations in hemophilia patients. Providing comprehensive information about the disease, treatment options, and lifestyle modifications, such as dietary changes and exercise regimens, can empower patients to actively participate in their care and optimize their health outcomes. Furthermore, psychological support and counseling services can help individuals cope with the psychosocial challenges associated with living with a chronic hematological disorder, ultimately improving their overall well-being and quality of life.[141-164]

Conclusion

The intricate interplay between hemophilia, HIV infection, and erythrocyte morphology alterations underscores the complexity of managing hematological complications in affected individuals. Erythrocyte morphology changes, including microcytosis, poikilocytosis, and alterations in membrane integrity, represent an important yet underrecognized aspect of these disorders, with significant clinical implications for disease progression and patient outcomes. Through elucidating the underlying mechanisms driving erythrocyte morphology alterations, clinicians and researchers can gain valuable insights into the pathophysiology of hematological complications in hemophilia patients with HIV co-infection. Moreover, understanding the clinical implications of these changes, such as exacerbation of anemia, increased thrombotic risk, and impaired tissue oxygenation, is essential for guiding targeted therapeutic interventions and optimizing patient care.

References

1. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood, The Journal of the American Society of Hematology. 2019;133(5):415-524.
2. Patton LL. Bleeding and clotting disorders. Burket's oral medicine: diagnosis and treatment. 10th ed. Hamilton (ON): BC Decker. 2003:454-477.
3. Livanou ME, Matsas A, Valsami S, Papadimitriou DT, Kontogiannis A, Christopoulos P. Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review. Life. 2023;13(6):1321.
4. Bauer KA. Current challenges in the management of hemophilia. Am J Manag Care. 2015;21(6 Suppl):S112-22.
5. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V. Haemophilia. Nature reviews Disease primers. 2021 Jun 24;7(1):45.
6. Karim MA, Jamal CY. A review on hemophilia in children. Bangladesh J Child Health. 2013;37(1):27-40.
7. Obeagu EI. Haemophilia B: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(1):14-20.
8. Okoroiwu IL, Obeagu EI, Egbuobi LN, Ibekwe AM, Vincent CC, Unaeze BC, Adike CN, Chijioke UO, Okafor CJ, Soremi AO, Chukwurah EF. Evaluation of Factor Viii and Factor

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

IX Activity among Primary School Children in Owerri, Imo State, Nigeria. Journal of Pharmaceutical Research International. 2021 Jul 3;33(34B):235-41.
9. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. Int. J. Curr. Res. Med. Sci. 2023;9(2):14-7.
10. Obeagu EI, Eze RI, Nwakulite A, Obeagu GU, Babar Q. AN UPDATE ON HAEMOPHILIA A. A. Journal of Medicine and Health Sciences. 2021;1(1):7-18.
11. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(8):22-6.
12. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-6.
13. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015;3:139-44.
14. Obeagu EI, Obeagu GU, Kama SC. Fibrin degradation product and Haemorrhage. Int. J. Curr. Res. Chem. Pharm. Sci. 2022;9(1):21-7.
15. Obeagu E, Nwosu D, Obeagu III G. Antithrombin III: A Review. Int. J. Curr. Res. Biol. Med. 2022;7(2):20-7.
16. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
17. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
18. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
19. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
20. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
21. McCann SR. A History of haematology: from Herodotus to HIV. Oxford University Press; 2016.
22. McCann SR. A History of haematology: from Herodotus to HIV. Oxford University Press; 2016.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

23. Provan D. Oxford handbook of clinical haematology. Oxford University Press, USA; 2009.
24. Doering CB, Archer D, Spencer HT. Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells. Advanced drug delivery reviews. 2010;62(12):1204-1212.
25. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
26. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
29. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
30. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
31. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
32. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
33. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
34. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA)

and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.

35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
40. Adeyemo TA, Adeyemo WL, Adediran A, Abd Jaleel AA, Akanmu AS. Orofacial manifestations of hematological disorders: Anemia and hemostatic disorders. Indian Journal of Dental Research. 2011;22(3):454-461.
41. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. In Seminars in thrombosis and hemostasis 2008; 01: 128-141.
42. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clinical chemistry. 2003;49(10):1573-1578.
43. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

44. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
45. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
46. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
50. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
53. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
54. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
55. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
56. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
57. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
58. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
59. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
60. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
61. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

62. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
63. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
64. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
65. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
66. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
67. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
68. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
69. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
70. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
71. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
72. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

73. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
74. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
75. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
76. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
77. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
78. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
79. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
80. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
81. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
82. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
83. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
84. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9): e37354.
85. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
86. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

87. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
88. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
89. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
90. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
91. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
92. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
93. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
94. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
95. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
96. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
97. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
98. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
99. Gonzalez VD. Innate and adaptive cellular immunity in chronic HCV and HIV-1 infection. Karolinska Institutet (Sweden); 2009.
100. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
101. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
102. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

103. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
104. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
105. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
106. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
107. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):38-58.
108. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. Elite Journal of HIV. 2024;2(3):14-26.
109. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health. 2024;2(1):52-63.
110. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
111. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. Elite Journal of Scientific Research and Review. 2024;2(1):37-50.
112. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
113. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science. 2024;2(3):59-72.
114. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
115. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
116. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
117. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV. 2024;2(2):60-73.
118. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

119. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science. 2024;2(2):33-46.
120. Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. Therapeutic advances in infectious disease. 2017;4(1):18-36.
121. Pooranagangadevi N, Padmapriyadarsini C. Treatment of tuberculosis and the drug interactions associated with HIV-TB co-infection treatment. Frontiers in Tropical Diseases. 2022; 3:834013.
122. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
123. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
124. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology. 2024;2(3):33-44.
125. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology. 2024;2(2):15-28.
126. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
127. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
128. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
129. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
130. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2 (3).:10-24.
131. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
132. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.
133. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
134. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):24-36.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

135. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
136. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
137. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2 (3).:42-57.
138. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review. 2024;2(1):1-6.
139. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
140. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
141. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science. 2024;2(2):16-29.
142. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
143. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science. 2024;2(2):1-7.
144. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
145. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
146. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review. 2024;2(1):42-60.
147. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-5.
148. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2 (3).:25-41.
149. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
150. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV. 2024;2(2):43-59.
151. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science. 2024;2(3):23-35.

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

152. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
153. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(3):84-99.
154. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science. 2024;2(2):20-35.
155. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. Elite Journal of Laboratory Medicine. 2024;2(2):30-46.
156. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
157. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health. 2024;2(1):35-51.
158. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. Elite Journal of Medicine. 2024;2(3):48-59.
159. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology. 2024;2(2):43-59.
160. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):14-32.
161. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review. 2024;2(1):17-41.
162. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. Elite Journal of Medicine. 2024;2(1):1-6.
163. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2 (3).:111-117.
164. Obeagu EI, Ngomo SSI. Erythrocyte Morphology in Hemophilia Patients Co-infected with HIV: A Review. *Elite Journal of Haematology, 2024; 2(5):* 72-89

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107

Citation: Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology, 2024; 2(5):* 90-107